DE10359528A1 - (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum - Google Patents

(S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum Download PDF

Info

Publication number
DE10359528A1
DE10359528A1 DE10359528A DE10359528A DE10359528A1 DE 10359528 A1 DE10359528 A1 DE 10359528A1 DE 10359528 A DE10359528 A DE 10359528A DE 10359528 A DE10359528 A DE 10359528A DE 10359528 A1 DE10359528 A1 DE 10359528A1
Authority
DE
Germany
Prior art keywords
hydroxytetralin
propylamino
alkyl
cycloalkyl
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE10359528A
Other languages
German (de)
English (en)
Inventor
Dieter Scheller
Klaus Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Priority to DE10359528A priority Critical patent/DE10359528A1/de
Priority to CN2004800373891A priority patent/CN1929829B/zh
Priority to DK04803781T priority patent/DK1694318T3/da
Priority to MXPA06006696A priority patent/MXPA06006696A/es
Priority to HK07101358.7A priority patent/HK1094421B/xx
Priority to EP04803781A priority patent/EP1694318B1/de
Priority to SI200430278T priority patent/SI1694318T1/sl
Priority to ES04803781T priority patent/ES2282923T3/es
Priority to DE502004003249T priority patent/DE502004003249D1/de
Priority to CA2547820A priority patent/CA2547820C/en
Priority to PL04803781T priority patent/PL1694318T3/pl
Priority to PT04803781T priority patent/PT1694318E/pt
Priority to RSP-2007/0117A priority patent/RS50536B/sr
Priority to HR20070175T priority patent/HRP20070175T3/xx
Priority to JP2006544295A priority patent/JP5253737B2/ja
Priority to AT04803781T priority patent/ATE356621T1/de
Priority to PCT/EP2004/014143 priority patent/WO2005058296A1/de
Priority to AU2004298341A priority patent/AU2004298341B2/en
Priority to US10/587,637 priority patent/US8609641B2/en
Priority to BRPI0417739-8A priority patent/BRPI0417739A/pt
Publication of DE10359528A1 publication Critical patent/DE10359528A1/de
Priority to IS8505A priority patent/IS2533B/is
Priority to KR1020067011512A priority patent/KR101083568B1/ko
Priority to CY20071100652T priority patent/CY1106589T1/el
Priority to US14/063,821 priority patent/US9108900B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE10359528A 2003-12-18 2003-12-18 (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum Ceased DE10359528A1 (de)

Priority Applications (24)

Application Number Priority Date Filing Date Title
DE10359528A DE10359528A1 (de) 2003-12-18 2003-12-18 (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
PT04803781T PT1694318E (pt) 2003-12-18 2004-12-13 Composição farmaçêutica.
HR20070175T HRP20070175T3 (hr) 2003-12-18 2004-12-13 (s)-2-n-propilamino-5-hidroksitetralin kao d3 agonist
MXPA06006696A MXPA06006696A (es) 2003-12-18 2004-12-13 (s)-2-n-propilamino-5-hidroxitetralina como un agonista-d3.
HK07101358.7A HK1094421B (en) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin as a d3-agonist
EP04803781A EP1694318B1 (de) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum
SI200430278T SI1694318T1 (sl) 2003-12-18 2004-12-13 (S)-2-N-propilamino-5-hidroksitetralin kot terapevtsko sredstvo z agonističnim učinkom na D3
ES04803781T ES2282923T3 (es) 2003-12-18 2004-12-13 (s)-2-n-propilamino-5-hidroxi-tetralina como agente terapeutico agonista de d3.
DE502004003249T DE502004003249D1 (en) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum
CA2547820A CA2547820C (en) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin as a d3 agonist
DK04803781T DK1694318T3 (da) 2003-12-18 2004-12-13 (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
CN2004800373891A CN1929829B (zh) 2003-12-18 2004-12-13 作为d3激动剂的(s)-2-n-丙基氨基-5-羟基四氢化萘
RSP-2007/0117A RS50536B (sr) 2003-12-18 2004-12-13 (s)-2-n-propilamino-5-hidroksitetralin kao d3-agonist
AT04803781T ATE356621T1 (de) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
PL04803781T PL1694318T3 (pl) 2003-12-18 2004-12-13 (S)-2-N-propyloamino-5-hydroksytetrahydronaftalen jako D3-agonistyczny środek terapeutyczny
JP2006544295A JP5253737B2 (ja) 2003-12-18 2004-12-13 Ｄ３アゴニスト性治療薬としての（ｓ）−２−ｎ−プロピルアミノ−５−ヒドロキシテトラリン
PCT/EP2004/014143 WO2005058296A1 (de) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum
AU2004298341A AU2004298341B2 (en) 2003-12-18 2004-12-13 (S)-2-N-propylamino-5-hydroxytetralin as a D3-agonist
US10/587,637 US8609641B2 (en) 2003-12-18 2004-12-13 (S)-2-N-propylamino-5-hydroxytetralin as a D3-agonist
BRPI0417739-8A BRPI0417739A (pt) 2003-12-18 2004-12-13 (s)-2-n-propilamino-5-hidroxitetralina como um agonista d3
IS8505A IS2533B (is) 2003-12-18 2006-06-12 (S)-2-N-própýlamínó-5-hýdroxýetralín sem D3-gerandefni
KR1020067011512A KR101083568B1 (ko) 2003-12-18 2006-06-12 Ｄ3 작용물질로서의(ｓ)-2-ｎ-프로필아미노-5-히드록시테트랄린
CY20071100652T CY1106589T1 (el) 2003-12-18 2007-05-14 (s)-2-ν-προπυλαμινο-5-υδροξυτετραλινη ως d3-αγωνιστικο θεραπευτικο μεσο
US14/063,821 US9108900B2 (en) 2003-12-18 2013-10-25 Method of treating diseases that respond to therapy by dopamine or dopamine agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10359528A DE10359528A1 (de) 2003-12-18 2003-12-18 (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum

Publications (1)

Publication Number Publication Date
DE10359528A1 true DE10359528A1 (de) 2005-07-28

Family

ID=34683532

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10359528A Ceased DE10359528A1 (de) 2003-12-18 2003-12-18 (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE502004003249T Expired - Lifetime DE502004003249D1 (en) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502004003249T Expired - Lifetime DE502004003249D1 (en) 2003-12-18 2004-12-13 (s)-2-n-propylamino-5-hydroxytetralin als d3-agonistisches therapeutikum

Country Status (21)

Country Link
US (2) US8609641B2 (https=)
EP (1) EP1694318B1 (https=)
JP (1) JP5253737B2 (https=)
KR (1) KR101083568B1 (https=)
CN (1) CN1929829B (https=)
AT (1) ATE356621T1 (https=)
AU (1) AU2004298341B2 (https=)
BR (1) BRPI0417739A (https=)
CA (1) CA2547820C (https=)
CY (1) CY1106589T1 (https=)
DE (2) DE10359528A1 (https=)
DK (1) DK1694318T3 (https=)
ES (1) ES2282923T3 (https=)
HR (1) HRP20070175T3 (https=)
IS (1) IS2533B (https=)
MX (1) MXPA06006696A (https=)
PL (1) PL1694318T3 (https=)
PT (1) PT1694318E (https=)
RS (1) RS50536B (https=)
SI (1) SI1694318T1 (https=)
WO (1) WO2005058296A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
ATE295726T1 (de) 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
SI2215072T1 (sl) 2007-11-28 2015-10-30 Ucb Pharma Gmbh Polimorfna oblika rotigotina
US8604242B2 (en) * 2008-10-13 2013-12-10 Interquim, S.A. Process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
JP5738875B2 (ja) 2009-10-16 2015-06-24 エピオメド セラピューティクス， インク． 催吐治療
US9925150B2 (en) 2009-12-22 2018-03-27 Lts Lohmann Therapie-Systeme Ag Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
ES2729824T3 (es) * 2011-04-08 2019-11-06 Laurus Labs Ltd Formas sólidas de compuestos antirretrovirales, procedimiento para la preparación y composición farmacéutica de los mismos
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
CN102634064B (zh) * 2012-04-10 2013-09-11 宁波长阳科技有限公司 一种含磷阻燃剂、阻燃聚酯薄膜及其制备方法
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2021206741A1 (en) * 2020-04-09 2021-10-14 Delahoussaye Kevin Modulating neurotransmitter concentration
DE102021213721A1 (de) * 2021-12-02 2023-06-07 Continental Reifen Deutschland Gmbh Verbindung, Kautschukmischung enthaltend die Verbindung, Fahrzeugreifen, der die Kautschukmischung in wenigstens einem Bauteil aufweist, Verfahren zur Herstellung der Verbindung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Antioxidationsmittel und/oder Farbstoff

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2333847A1 (de) * 1972-07-03 1974-01-24 Squibb & Sons Inc Tetrahydronaphthole, ihre salze und diese verbindungen enthaltende arzneimittel
DE3417859A1 (de) * 1984-05-07 1985-11-14 Nelson Research & Development Co., Irvine, Calif. Therapeutische zubereitung zur behandlung des parkinsonismus

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3062971D1 (en) 1979-09-14 1983-06-09 Sandoz Ag Derivatives of tetraline, their preparation and medicaments containing these compounds
US4465692A (en) * 1982-01-03 1984-08-14 Nelson Research & Development Company Selective D-2 dopamine receptor agonist
US5177112A (en) 1983-01-03 1993-01-05 Whitby Research, Inc. Substituted 2-aminotetralins
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
WO1993023035A2 (en) 1992-05-18 1993-11-25 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
SE9301732D0 (sv) 1993-05-18 1993-05-18 Haakan Wilhelm Wikstroem New centrally acting 5-,6-,7-, and 8-substituted sulphone esters of n-monosubstituted 2-aminotetralins
US5382596A (en) 1993-08-05 1995-01-17 Whitby Research, Inc. Substituted 2-aminotetralins
US5442117A (en) 1993-12-13 1995-08-15 Albemarle Corporation Enantiomeric resolution
IT1292155B1 (it) 1997-06-13 1999-01-25 Zambon Spa Derivati naftotiazolonici attivi sul recettore dopaminergico d 3
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
HK1049156B (en) * 1999-11-23 2004-12-10 Ucb Manufacturing Ireland Limited Improved process for preparing nitrogen-substituted aminotetralins
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20030027793A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
PT1256339E (pt) 2001-05-08 2004-02-27 Lohmann Therapie Syst Lts Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
EP1256340B1 (en) 2001-05-08 2003-08-13 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
FR2829028B1 (fr) 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
HU227543B1 (en) 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US20060263419A1 (en) 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EP1494664A2 (en) 2002-04-18 2005-01-12 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
US20040048779A1 (en) 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
DE10220230A1 (de) 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US20060216336A1 (en) 2002-05-07 2006-09-28 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US8211462B2 (en) 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE10234673B4 (de) 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
ATE295726T1 (de) 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
DE10334187A1 (de) 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US20050197385A1 (en) 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
TWI392670B (zh) 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
SI2215072T1 (sl) 2007-11-28 2015-10-30 Ucb Pharma Gmbh Polimorfna oblika rotigotina
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
US9925150B2 (en) 2009-12-22 2018-03-27 Lts Lohmann Therapie-Systeme Ag Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2333847A1 (de) * 1972-07-03 1974-01-24 Squibb & Sons Inc Tetrahydronaphthole, ihre salze und diese verbindungen enthaltende arzneimittel
DE3417859A1 (de) * 1984-05-07 1985-11-14 Nelson Research & Development Co., Irvine, Calif. Therapeutische zubereitung zur behandlung des parkinsonismus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Hacksell, U. [u.a.]: In: J. Med. Chem., 1979, Vol. 22, S. 1469-1475 *
Swart, P.J. [u.a.]: In: J. Anal. Toxicol., 1994, Vol. 18, S. 71-77 *
van Vliet, L.A. [u.a.]: In: J. Med. Chem., 1996, Vol. 39, S. 4233-4237 *
Wilcox, R.E. und McMillen, B.A.: In: Alcohol, 1998, Vol. 15, S. 161-177 *

Also Published As

Publication number Publication date
IS2533B (is) 2009-07-15
AU2004298341B2 (en) 2011-03-10
KR20060126500A (ko) 2006-12-07
CA2547820C (en) 2013-02-19
IS8505A (is) 2006-06-12
ES2282923T3 (es) 2007-10-16
MXPA06006696A (es) 2006-08-31
AU2004298341A1 (en) 2005-06-30
US9108900B2 (en) 2015-08-18
EP1694318A1 (de) 2006-08-30
PT1694318E (pt) 2007-05-31
RS50536B (sr) 2010-05-07
CN1929829A (zh) 2007-03-14
BRPI0417739A (pt) 2007-04-03
PL1694318T3 (pl) 2007-07-31
HRP20070175T3 (hr) 2007-06-30
KR101083568B1 (ko) 2011-11-14
EP1694318B1 (de) 2007-03-14
SI1694318T1 (sl) 2007-08-31
DK1694318T3 (da) 2007-06-25
JP5253737B2 (ja) 2013-07-31
ATE356621T1 (de) 2007-04-15
US20070197480A1 (en) 2007-08-23
CN1929829B (zh) 2010-12-15
DE502004003249D1 (en) 2007-04-26
CY1106589T1 (el) 2012-01-25
CA2547820A1 (en) 2005-06-30
JP2007514674A (ja) 2007-06-07
US20140051768A1 (en) 2014-02-20
WO2005058296A1 (de) 2005-06-30
HK1094421A1 (en) 2007-03-30
US8609641B2 (en) 2013-12-17

Similar Documents

Publication Publication Date Title
DE10359528A1 (de) (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
DE2901032C2 (de) Substituierte Morpholin-Derivate und deren Verwendung
EP1727539B1 (de) Verwendung von rotigotin zur behandlung und prävention des parkinson-plus-syndroms
DE3687288T2 (de) Chinuclidinderivate.
DE69814688T2 (de) Benzylidene- und cinnamylidene-anabaseine als neuronale nikotin alpha-7 rezeptoragonisten
DE69914229T2 (de) Neuartige Ester abgeleitet von substituierten Phenyl-Zyklohexyl-Verbindungen
DE69725153T2 (de) Kaliumkanal-blocker
DE69332559T2 (de) 2,3,4,5-tetrahydro-1h-3-benzazepinen mit anti-psychotisch wirkung, und synthese von alfa-substituierten-arylacetamiden
EP1105371B1 (de) Aminosäureester von arylsulfonamiden und analoga
DE69300532T2 (de) Naphtylalkylamine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
DE69428903T2 (de) Substituierte 2-aminotetraline
EP1105370A1 (de) Neue arylsulfonamide und analoga
EP1758860B1 (de) Gesättigte und ungesättigte 3-pyridyl-benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
DD201139A5 (de) Verfahren zur herstellung von (-)-n-methyl-3-(2-methylphenoxy)-3-phenylpropylamin und seinen pharmazeutisch unbedenklichen salzen
DE102004054634A1 (de) Azaindolcarboxamide
DE69935331T2 (de) Verfahren und verbindungen zur behandlung der depression
DE69813228T2 (de) Alifatische propargylamine als zelluläres rettungsmittel
CH626344A5 (https=)
DE69713067T2 (de) Aminotetralinderivate, deren zusammensetzungen sowie deren verwendung
DE60213116T2 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DE102005028845A1 (de) Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
DE69402463T2 (de) (7S)-7-(2R)-2-(3-Chlorophenyl)-2-Hydoxyethylamino-5,6,7,8-Tetrahydronaphtalen-2-yloxy Essigsäure, ihre pharmazeutisch akzeptablen Salze, mit Beta-3-adrenergischer agonistischer Aktivität und diese enthaltende pharmazeutische Zusammensetzungen
DE69608891T2 (de) Tetraline mit einem phenylsubstituenten am aromatischen ring und ihre verwendung in der behandlung von epilepsie, schlaganfall und gehirn- oder rückenmarkstrauma
JPH04178356A (ja) 光学活性なベンジルアルコール誘導体及びその用途
DE60211186T2 (de) Neue verwendung substituierter aminomethylchromane

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection